

Sprint Bioscience collaborates to expand its MASH programme into inflammation

Sprint Bioscience today announces that the company has entered a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore, regarding the therapeutic expansion of Sprint Bioscience's MASH (metabolic dysfunction-associated steatohepatitis) programme into inflammatory diseases.

In the collaboration, compounds developed by Sprint Bioscience in its MASH programme will be evaluated by EDDC, Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR), in inflammatory disease models to assess their broader anti-inflammatory effects. After the evaluation, EDDC will have the option to take over and further develop the program. Any future revenues will be shared between Sprint Bioscience and EDDC based on the investment each party has made in the programme.

"We are very pleased that our programme is attracting interest in inflammatory conditions as well, and excited at the potential to help patients with various inflammatory and autoimmune diseases. Given Sprint Bioscience's focus on oncology, we see this collaboration as an excellent opportunity to gain access to the expertise required to evaluate these opportunities, thereby maximising the value of the programme," said Johan Emilsson, CEO of Sprint Bioscience.

"EDDC looks forward to collaborating with Sprint Bioscience to expand our portfolio in inflammation and immunology. This partnership builds on a strong foundation of scientific groundwork that has already been done in this programme, and we are excited to explore its potential to provide meaningful solutions for patients living with debilitating inflammatory and autoimmune diseases," said Prof Damian O'Connell, CEO of EDDC.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience

Tel: +46 (8) 411 44 55

Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small-molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase, and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

About the Experimental Drug Development Centre (EDDC)

The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.

This information is information that Sprint Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-18 19:18 CEST.

Attachments

[Sprint Bioscience collaborates to expand its MASH programme into inflammation](#)